Autologous TILs for Recurrent Ovarian Cancer

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This interventional study collects tumor tissue from participants to grow enhanced autologous tumor-infiltrating lymphocytes (CHA-TIL) in the lab. The prepared cells are then given back to the patient through a single IV infusion to assess safety and any signs of benefit over 6 months. The trial focuses on safety first, with preliminary checks on efficacy in recurrent ovarian cancer. Eligible participants must have a biopsy- or surgery-accessible tumor and no immunodeficiency or autoimmune conditions that could worsen with immunotherapy.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Recurrent ovarian cancer
* There is a cancerous lesion that can be removed by biopsy or surgery.

Exclusion Criteria:

* Patient with immunodeficiency or autoimmune diseases that may be exacerbated by immunotherapy
* Patient deemed unsuitable by the principal investigator

Where it's running

• Bundang CHA Medical Center
  Gyeonggi-do, Bundang-gu, South Korea Recruiting

Study contacts

• Study coordinator: Yong Wha Moon
• Email: ymoon@cha.ac.kr
• Phone: 82-31-780-3436

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• SYS6041 in combination therapy for recurrent ovarian cancer

  This study tests SYS6041 combined with other cancer drugs in adults whose ovarian cancer has come back to see if it’s safe and possibly effective.

  Recruiting Phase 2 CSPC Megalith Biopharmaceutical Co.,Ltd. · Shanghai, Shanghai Municipality · NCT07714668

• Reirradiation and Total Ablative Strategies for Recurrent Gynecologic Cancer (REGYNERA-tion) Registry

  This registry tests how reirradiation and total ablative strategies are used in real-world care for adults with recurrent gynecologic cancers and tracks outcomes to see what happens after these treatments.

  Recruiting Affidea Nu-med Center of Oncological DIagnostics and Therapy · Zamość, Lublin Voivodeship · NCT07667192

• CapsuleX combined with cisplatin for platinum-resistant recurrent ovarian cancer

  This study will try adding CapsuleX to cisplatin to see if it helps people with platinum-resistant recurrent ovarian cancer have better tumor responses.

  Recruiting The First Hospital of Jilin University · Changchun, Jilin · NCT07495384

• HS-10502 combination treatment for advanced solid tumors

  This study will test whether the oral drug HS-10502, given with other cancer medicines, is safe and can help people with advanced solid tumors such as recurrent ovarian cancer, HER2‑negative or triple‑negative breast cancer, and advanced prostate cancer.

  Recruiting Phase 1 Jiangsu Hansoh Pharmaceutical Co., Ltd. · Shanghai, Shanghai Municipality · NCT06769425

• Combination therapy for recurrent ovarian cancer

  This study is testing a new combination of treatments for women with recurrent ovarian cancer to see if it can help them feel better and improve their outcomes.

  Recruiting Phase 2 Akeso · Shanghai · NCT06560112

• CPI-0209 combined with Carboplatin for recurrent ovarian cancer

  This study is testing if a new treatment called CPI-0209, when combined with Carboplatin, can help women with recurrent ovarian cancer feel better and stay cancer-free longer.

  Recruiting Phase 1 University of Pittsburgh · Pittsburgh, Pennsylvania · NCT05942300

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.